Evotec has entered a multi-year research collaboration and option and license agreement with Pfizer, aimed at discovering novel therapies for metabolic and infectious diseases.
The research will take place at Evotec's facilities in France, including Campus Curie, a state-of-the-art research site with capabilities including high throughput screening, in vitro and in vivo biology, proteomics, and metabolomics. The research will be supported by funding from Pfizer, and Evotec will also be eligible for milestone and royalty payments.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.